Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 28, 2008. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting held on May 21, 2008.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes related to a share buyback.
- Shares Purchased: 3,040,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,117.79 pence per share.
- Treasury Shares Held: 484,194,158 shares (representing 9.06% of total voting rights).
- Shares in Issue: 5,342,675,996 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the Company's share capital through the cancellation of 3,040,000 shares purchased on May 28, 2008. This transaction increased the proportion of shares held in Treasury to 9.06% of total voting rights.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,342,675,996) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (484,194,158) and its impact on voting rights (9.06%).
- Note that this filing does not contain financial performance data; refer to Form 20-F for revenue and earnings metrics.